Air Products & Chemicals, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Air Products & Chemicals, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $12.04B | Nov 20, 2025 |
| FY2025 | Sep 30, 2024 | $12.10B | Nov 20, 2025 |
| FY2025 | Sep 30, 2023 | $12.60B | Nov 20, 2025 |
| FY2024 | Sep 30, 2022 | $12.70B | Nov 21, 2024 |
| FY2023 | Sep 30, 2021 | $10.32B | Nov 16, 2023 |
| FY2020 | Sep 30, 2020 | $2.32B | Nov 19, 2020 |
| FY2020 | Jun 30, 2020 | $2.07B | Nov 19, 2020 |
| FY2020 | Mar 31, 2020 | $2.22B | Nov 19, 2020 |
| FY2020 | Dec 31, 2019 | $2.25B | Nov 19, 2020 |
| FY2020 | Sep 30, 2019 | $2.28B | Nov 19, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Sep 30, 2017 | $2.20B | Nov 16, 2017 |
| FY2017 | Jun 30, 2017 | $2.12B | Nov 16, 2017 |
| FY2017 | Mar 31, 2017 | $1.98B | Nov 16, 2017 |
| FY2017 | Dec 31, 2016 | $1.88B | Nov 16, 2017 |
| FY2017 | Sep 30, 2016 | $1.95B | Nov 16, 2017 |
| FY2017 | Jun 30, 2016 | $1.91B | Nov 16, 2017 |
| FY2017 | Mar 31, 2016 | $1.78B | Nov 16, 2017 |
| FY2017 | Dec 31, 2015 | $1.87B | Nov 16, 2017 |
| FY2016 | Sep 30, 2015 | $2.45B | Nov 21, 2016 |
| FY2016 | Jun 30, 2015 | $2.47B | Nov 21, 2016 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Sep 30, 2020 | $753.60M | Nov 19, 2020 |
| FY2020 | Jun 30, 2020 | $720.30M | Nov 19, 2020 |
| FY2020 | Mar 31, 2020 | $756.20M | Nov 19, 2020 |
| FY2020 | Dec 31, 2019 | $768.10M | Nov 19, 2020 |
| FY2020 | Sep 30, 2019 | $792.40M | Nov 19, 2020 |
| FY2020 | Jun 30, 2019 | $758.00M | Nov 19, 2020 |
| FY2020 | Mar 31, 2019 | $713.00M | Nov 19, 2020 |
| FY2020 | Dec 31, 2018 | $651.00M | Nov 19, 2020 |
| FY2019 | Sep 30, 2018 | $733.10M | Nov 26, 2019 |
| FY2019 | Jun 30, 2018 | $713.60M | Nov 26, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($394.50M) | Nov 20, 2025 |
| FY2025 | Sep 30, 2024 | $3.83B | Nov 20, 2025 |
| FY2025 | Sep 30, 2023 | $2.30B | Nov 20, 2025 |
| FY2024 | Sep 30, 2022 | $2.26B | Nov 21, 2024 |
| FY2023 | Sep 30, 2021 | $2.10B | Nov 16, 2023 |
| FY2020 | Sep 30, 2020 | $486.80M | Nov 19, 2020 |
| FY2020 | Jun 30, 2020 | $446.50M | Nov 19, 2020 |
| FY2020 | Mar 31, 2020 | $477.80M | Nov 19, 2020 |
| FY2020 | Dec 31, 2019 | $475.60M | Nov 19, 2020 |
| FY2020 | Sep 30, 2019 | $503.20M | Nov 19, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($877.00M) | Nov 20, 2025 |
| FY2025 | Sep 30, 2024 | $4.47B | Nov 20, 2025 |
| FY2025 | Sep 30, 2023 | $2.49B | Nov 20, 2025 |
| FY2024 | Sep 30, 2022 | $2.34B | Nov 21, 2024 |
| FY2023 | Sep 30, 2021 | $2.28B | Nov 16, 2023 |
| FY2020 | Sep 30, 2020 | $560.20M | Nov 19, 2020 |
| FY2020 | Jun 30, 2020 | $539.20M | Nov 19, 2020 |
| FY2020 | Mar 31, 2020 | $577.20M | Nov 19, 2020 |
| FY2020 | Dec 31, 2019 | $561.00M | Nov 19, 2020 |
| FY2020 | Sep 30, 2019 | $603.20M | Nov 19, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $96.30M | Nov 20, 2025 |
| FY2025 | Sep 30, 2024 | $100.20M | Nov 20, 2025 |
| FY2025 | Sep 30, 2023 | $105.60M | Nov 20, 2025 |
| FY2024 | Sep 30, 2022 | $102.90M | Nov 21, 2024 |
| FY2023 | Sep 30, 2021 | $93.50M | Nov 16, 2023 |
| FY2022 | Sep 30, 2020 | $83.90M | Nov 22, 2022 |
| FY2021 | Sep 30, 2019 | $72.90M | Nov 18, 2021 |
| FY2020 | Sep 30, 2018 | $64.50M | Nov 19, 2020 |
| FY2019 | Sep 30, 2017 | $57.60M | Nov 26, 2019 |
| FY2018 | Sep 30, 2016 | $71.80M | Nov 20, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $906.10M | Nov 20, 2025 |
| FY2025 | Sep 30, 2024 | $942.40M | Nov 20, 2025 |
| FY2025 | Sep 30, 2023 | $957.00M | Nov 20, 2025 |
| FY2024 | Sep 30, 2022 | $900.60M | Nov 21, 2024 |
| FY2023 | Sep 30, 2021 | $828.40M | Nov 16, 2023 |
| FY2022 | Sep 30, 2020 | $775.90M | Nov 22, 2022 |
| FY2021 | Sep 30, 2019 | $750.00M | Nov 18, 2021 |
| FY2020 | Sep 30, 2018 | $760.80M | Nov 19, 2020 |
| FY2019 | Sep 30, 2017 | $713.50M | Nov 26, 2019 |
| FY2018 | Sep 30, 2016 | $683.80M | Nov 20, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2011 | Sep 30, 2011 | $1.75B | Nov 22, 2011 |
| FY2011 | Sep 30, 2010 | $1.52B | Nov 22, 2011 |
| FY2011 | Sep 30, 2009 | $1.33B | Nov 22, 2011 |
| FY2010 | Sep 30, 2008 | $1.66B | Nov 23, 2010 |
| FY2009 | Sep 30, 2007 | $1.50B | Nov 25, 2009 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $7.02B | Nov 20, 2025 |
| FY2025 | Sep 30, 2024 | $6.80B | Nov 20, 2025 |
| FY2025 | Sep 30, 2023 | $4.63B | Nov 20, 2025 |
| FY2024 | Sep 30, 2022 | $2.93B | Nov 21, 2024 |
| FY2023 | Sep 30, 2021 | $2.46B | Nov 16, 2023 |
| FY2022 | Sep 30, 2020 | $2.51B | Nov 22, 2022 |
| FY2021 | Sep 30, 2019 | $1.99B | Nov 18, 2021 |
| FY2020 | Sep 30, 2018 | $1.57B | Nov 19, 2020 |
| FY2019 | Sep 30, 2017 | $1.04B | Nov 26, 2019 |
| FY2018 | Sep 30, 2016 | $907.70M | Nov 20, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $41.06B | Nov 20, 2025 |
| FY2025 | Sep 30, 2024 | $39.57B | Nov 20, 2025 |
| FY2024 | Sep 30, 2023 | $32.00B | Nov 21, 2024 |
| FY2023 | Sep 30, 2022 | $27.19B | Nov 16, 2023 |
| FY2022 | Sep 30, 2021 | $26.86B | Nov 22, 2022 |
| FY2021 | Sep 30, 2020 | $25.17B | Nov 18, 2021 |
| FY2020 | Sep 30, 2019 | $18.94B | Nov 19, 2020 |
| FY2018 | Oct 1, 2018 | $19.20B | Nov 20, 2018 |
| FY2019 | Sep 30, 2018 | $19.18B | Nov 26, 2019 |
| FY2018 | Sep 30, 2017 | $18.47B | Nov 20, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $23.71B | Nov 20, 2025 |
| FY2025 | Sep 30, 2024 | $20.90B | Nov 20, 2025 |
| FY2024 | Sep 30, 2023 | $16.34B | Nov 21, 2024 |
| FY2023 | Sep 30, 2022 | $13.49B | Nov 16, 2023 |
| FY2022 | Sep 30, 2021 | $12.77B | Nov 22, 2022 |
| FY2021 | Sep 30, 2020 | $12.73B | Nov 18, 2021 |
| FY2020 | Sep 30, 2019 | $7.55B | Nov 19, 2020 |
| FY2018 | Oct 1, 2018 | $8.03B | Nov 20, 2018 |
| FY2019 | Sep 30, 2018 | $8.00B | Nov 26, 2019 |
| FY2018 | Sep 30, 2017 | $8.28B | Nov 20, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $15.02B | Nov 20, 2025 |
| FY2025 | Sep 30, 2024 | $17.04B | Nov 20, 2025 |
| FY2024 | Sep 30, 2023 | $14.31B | Nov 21, 2024 |
| FY2023 | Sep 30, 2022 | $13.14B | Nov 16, 2023 |
| FY2022 | Sep 30, 2021 | $13.54B | Nov 22, 2022 |
| FY2021 | Sep 30, 2020 | $12.08B | Nov 18, 2021 |
| FY2020 | Sep 30, 2019 | $11.05B | Nov 19, 2020 |
| FY2019 | Sep 30, 2018 | $10.86B | Nov 26, 2019 |
| FY2018 | Sep 30, 2017 | $10.09B | Nov 20, 2018 |
| FY2017 | Sep 30, 2016 | $7.08B | Nov 16, 2017 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $963.90M | Nov 20, 2025 |
| FY2025 | Sep 30, 2024 | $905.10M | Nov 20, 2025 |
| FY2025 | Sep 30, 2023 | $861.70M | Nov 20, 2025 |
| FY2024 | Sep 30, 2022 | $823.00M | Nov 21, 2024 |
| FY2023 | Sep 30, 2021 | $911.50M | Nov 16, 2023 |
| FY2022 | Sep 30, 2020 | $891.50M | Nov 22, 2022 |
| FY2021 | Sep 30, 2019 | $797.10M | Nov 18, 2021 |
| FY2020 | Sep 30, 2018 | $788.90M | Nov 19, 2020 |
| FY2019 | Sep 30, 2017 | $721.50M | Nov 26, 2019 |
| FY2018 | Sep 30, 2016 | $845.10M | Nov 20, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $17.56B | Nov 20, 2025 |
| FY2025 | Sep 30, 2024 | $19.55B | Nov 20, 2025 |
| FY2024 | Sep 30, 2023 | $17.29B | Nov 21, 2024 |
| FY2023 | Sep 30, 2022 | $16.52B | Nov 16, 2023 |
| FY2022 | Sep 30, 2021 | $15.68B | Nov 22, 2022 |
| FY2021 | Sep 30, 2020 | $14.88B | Nov 18, 2021 |
| FY2020 | Sep 30, 2019 | $14.14B | Nov 19, 2020 |
| FY2019 | Sep 30, 2018 | $13.41B | Nov 26, 2019 |
| FY2018 | Sep 30, 2017 | $12.85B | Nov 20, 2018 |
| FY2017 | Sep 30, 2016 | $10.48B | Nov 16, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $1.86B | Nov 20, 2025 |
| FY2025 | Sep 30, 2024 | $2.98B | Nov 20, 2025 |
| FY2024 | Sep 30, 2023 | $1.62B | Nov 21, 2024 |
| FY2023 | Sep 30, 2022 | $2.71B | Nov 16, 2023 |
| FY2022 | Sep 30, 2021 | $4.47B | Nov 22, 2022 |
| FY2021 | Sep 30, 2020 | $5.25B | Nov 18, 2021 |
| FY2020 | Sep 30, 2019 | $2.25B | Nov 19, 2020 |
| FY2018 | Oct 1, 2018 | $2.79B | Nov 20, 2018 |
| FY2019 | Sep 30, 2018 | $2.79B | Nov 26, 2019 |
| FY2018 | Sep 30, 2017 | $3.27B | Nov 20, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Sep 30, 2016 | $5.29B | Nov 21, 2016 |
| FY2016 | Sep 30, 2015 | $4.38B | Nov 21, 2016 |
| FY2015 | Sep 30, 2014 | $4.89B | Nov 24, 2015 |
| FY2014 | Sep 30, 2013 | $5.56B | Nov 24, 2014 |
| FY2013 | Sep 30, 2012 | $4.66B | Nov 26, 2013 |
| FY2012 | Sep 30, 2011 | $4.00B | Nov 20, 2012 |
| FY2011 | Sep 30, 2010 | $3.84B | Nov 22, 2011 |
| FY2010 | Sep 30, 2009 | $4.17B | Nov 23, 2010 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | (1) | Nov 20, 2025 |
| FY2025 | Sep 30, 2024 | 17 | Nov 20, 2025 |
| FY2025 | Sep 30, 2023 | 10 | Nov 20, 2025 |
| FY2024 | Sep 30, 2022 | 10 | Nov 21, 2024 |
| FY2023 | Sep 30, 2021 | 9 | Nov 16, 2023 |
| FY2020 | Sep 30, 2020 | 2 | Nov 19, 2020 |
| FY2020 | Jun 30, 2020 | 2 | Nov 19, 2020 |
| FY2020 | Mar 31, 2020 | 2 | Nov 19, 2020 |
| FY2020 | Dec 31, 2019 | 2 | Nov 19, 2020 |
| FY2020 | Sep 30, 2019 | 2 | Nov 19, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | (1) | Nov 20, 2025 |
| FY2025 | Sep 30, 2024 | 17 | Nov 20, 2025 |
| FY2025 | Sep 30, 2023 | 10 | Nov 20, 2025 |
| FY2024 | Sep 30, 2022 | 10 | Nov 21, 2024 |
| FY2023 | Sep 30, 2021 | 9 | Nov 16, 2023 |
| FY2020 | Sep 30, 2020 | 2 | Nov 19, 2020 |
| FY2020 | Jun 30, 2020 | 2 | Nov 19, 2020 |
| FY2020 | Mar 31, 2020 | 2 | Nov 19, 2020 |
| FY2020 | Dec 31, 2019 | 2 | Nov 19, 2020 |
| FY2020 | Sep 30, 2019 | 2 | Nov 19, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 222.59M | Nov 20, 2025 |
| FY2025 | Sep 30, 2024 | 222.37M | Nov 20, 2025 |
| FY2025 | Sep 30, 2023 | 222.20M | Nov 20, 2025 |
| FY2025 | Sep 30, 2022 | 221.84M | Nov 20, 2025 |
| FY2024 | Sep 30, 2021 | 221.40M | Nov 21, 2024 |
| FY2023 | Sep 30, 2020 | 221.02M | Nov 16, 2023 |
| FY2022 | Sep 30, 2019 | 220.42M | Nov 22, 2022 |
| FY2021 | Sep 30, 2018 | 219.52M | Nov 18, 2021 |
| FY2020 | Sep 30, 2017 | 218.35M | Nov 19, 2020 |
| FY2019 | Sep 30, 2016 | 217.35M | Nov 26, 2019 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $1.58B | Nov 20, 2025 |
| FY2025 | Sep 30, 2024 | $1.56B | Nov 20, 2025 |
| FY2025 | Sep 30, 2023 | $1.50B | Nov 20, 2025 |
| FY2024 | Sep 30, 2022 | $1.38B | Nov 21, 2024 |
| FY2023 | Sep 30, 2021 | $1.26B | Nov 16, 2023 |
| FY2022 | Sep 30, 2020 | $1.10B | Nov 22, 2022 |
| FY2021 | Sep 30, 2019 | $994.00M | Nov 18, 2021 |
| FY2020 | Sep 30, 2018 | $897.80M | Nov 19, 2020 |
| FY2019 | Sep 30, 2017 | $787.90M | Nov 26, 2019 |
| FY2018 | Sep 30, 2016 | $721.20M | Nov 20, 2018 |